| Literature DB >> 16102740 |
Abstract
BACKGROUND: As we enter the post-genome sequencing era and begin to sift through the enormous amount of genetic information now available, the need for technologies that allow rapid, cost-effective, high-throughput detection of specific nucleic acid sequences becomes apparent. Multiplexing technologies, which allow for simultaneous detection of multiple nucleic acid sequences in a single reaction, can greatly reduce the time, cost and labor associated with single reaction detection technologies.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16102740 PMCID: PMC7124242 DOI: 10.1016/j.cccn.2005.06.023
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786
Fig. 1Luminex xMAP system and components. The four main components of the xMAP system are shown, clockwise from top-right: biomolecular reactants; fluorescently color-coded microspheres; fluidics and optics; and high-speed digital signal processing. The Luminex 100 analyzer with XY platform and sheath delivery system is pictured in the center.
Fig. 2Diagram of the microsphere-based direct hybridization assay format. Target DNA is PCR-amplified. One of the primers is biotinylated. The amplified products are denatured, hybridized to allele-specific probe-coupled microsphere sets and labeled for detection with streptavidin-R-phycoerythrin.
Fig. 3Diagram of the microsphere-based competitive hybridization assay format. Left: In the absence of target DNA, the biotinylated competitor oligonucleotides hybridize to the allele-specific probe-coupled microsphere sets. The hybridized microsphere sets are labeled with streptavidin-R-phycoerythrin, resulting in 100% signal. Right: When target DNA is present, the biotinylated competitor oligonucleotides hybridize to the target DNA instead of the allele-specific probe-coupled microsphere sets. The target DNA/competitor oligonucleotide hybrids are labeled with streptavidin-R-phycoerythrin, resulting in a reduction of signal on the allele-specific probe-coupled microsphere sets.
Fig. 4Diagram of assay format using solution-based genotyping with microsphere capture. A. Solution-based enzymatic genotyping assay is performed, incorporating the unique capture sequences into the products. B. Address probe-coupled microsphere sets. C. Products are captured onto the microspheres through hybridization of the capture and address sequences, and labeled with streptavidin-R-phycoerythrin.
Fig. 5Diagram of ASPE, OLA and SBCE procedures used for addressed microsphere capture assays. ASPE: 1. Target DNA is combined with capture sequence-tagged allele specific primers and denatured; 2. Target DNA and primers are annealed in a reaction containing a DNA polymerase and dNTPs (one of which is biotinylated); 3. Primer extension; and 4. Capture sequence-tagged ASPE products. OLA: 1. Target DNA is combined with capture sequence-tagged allele specific probes and denatured; 2. Target DNA and probes are annealed in a reaction containing a DNA ligase and biotinylated reporter probe; 3. Oligonucleotide ligation; and 4. Capture sequence-tagged OLA products. SBCE: 1. Target DNA is combined with a capture sequence-tagged primer (in separate reactions for each allele) and denatured; 2. Target DNA and primer is annealed in a reaction containing a DNA polymerase and a biotinylated ddNTP; 3. Single base primer extension; and 4. Capture sequence-tagged SBCE products are multiplexed for detection.
Commercially available xMAP-based assay kits for nucleic acid detection
| Company | Application | Analyte(s) | Assay format | Features |
|---|---|---|---|---|
| Ambion Diagnostics (Austin, TX) | Genetic disease screening | Direct hybridization | Homogeneous, Signature Script analysis software | |
| Marligen Biosciences, Inc. (Ijamsville, MD) | SNP genotyping | Y chromosome SNPs | Direct hybridization | Direct fluorescent labeling of PCR products |
| Mitochondrial DNA polymorphisms | ||||
| One Lambda, Inc. (Canoga Park, CA) | HLA DNA typing | HLA A, B, C; DRB1, DRB3,4,5; DQB1 | Direct hybridization | Internal positive and negative controls, approved for IVD use |
| Proactive Medical Technologies, Inc. (Austin, TX) | Infectious disease | Direct hybridization with microsphere capture | Proprietary MDD™ technology | |
| Tepnel Lifecodes (Stamford, CT) | HLA DNA typing | HLA A, B, C, DRB, DQB | Direct hybridization | Asymmetric PCR, homogeneous, internal positive control, CE marked for IVD in Europe |
| Tm Bioscience (Toronto, Ontario) | SNP genotyping | ASPE with microsphere capture | Tag-It™ universal array platform | |
| Genetic disease screening | ||||